Choice of therapeutic anti-seizure medication in patients with brain tumour by Laghari, Altaf Ali et al.
Masthead Logo eCommons@AKU
Section of Neurosurgery Department of Surgery
March 2019
Choice of therapeutic anti-seizure medication in
patients with brain tumour
Altaf Ali Laghari
Aga Khan University, altaf.laghari@aku.edu
Syed Ijlal Ahmed
Aga Khan University
Namra Qadeer
Aga Khan University
Muhammad Shahzad Shamim
Aga Khan University, shahzad.shamim@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg
Recommended Citation
Laghari, A. A., Ahmed, S. I., Qadeer, N., Shamim, M. (2019). Choice of therapeutic anti-seizure medication in patients with brain
tumour. Journal of Pakistan Medical Association, 69(3), 442-444.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/186
Vol. 69, No. 3, March 2019
442
Abstract 
Seizures are common in patients with brain tumours, 
even though prophylactic anti-seizure treatment for all 
patients with brain tumours is not recommended. Newer 
anti-epileptic drugs have shown benefits that outweigh 
the side effects of treatment and can also be given in 
combination with traditional anti-epileptic drugs. The 
authors have reviewed the literature on the various 
combinations of anti-epileptics in patients with seizures 
and brain tumours.  
Keywords: Seizures, anti-epileptic drugs, brain 
tumours. 
Introduction 
Seizures may be the presenting symptom of a brain 
tumour, which is reported in a substantial number of 
patients, especially those with intra-axial, supratentorial 
brain tumours. It is postulated that the tissue in and 
around brain tumours may exhibit epileptogenic 
properties due to dysregulated neuronal activity, 
impaired glial cell function, and modified vascularity.1 The 
presence of abnormal, neoplastic tissue leads to structural 
and functional alteration of surrounding tissue due to 
oedema, vascular insufficiency, inflammation, and release 
of metabolically active molecules, all of which may 
predispose to seizure activity. Understanding these 
changes may lead to a better control of seizures in 
patients with brain tumours. In this article we aim to 
review literature addressing pharmaceutical 
management of seizures in patients with brain tumours. 
This review will not address the role of prophylactic anti-
epileptics in patients with brain tumours. 
Review Of Evidence 
Valproic acid or valproate, is a conventional anti-epileptic 
drug with properties of a histone deacetylase inhibitor 
(HDACi). HDACi plays a key role in gene expression and 
epigenetic regulation and has also been used as an 
anticancer agent. Redjal et al.2, report valproate to be 
associated with improved survival in patients with high 
grade glioma and GBM in a dose-dependent manner. 
However, in patients with grade II and III gliomas, it is 
associated with an 18% increased risk of tumour 
progression or death, and every additional 100g of 
valproate raises the risk of progression or death by 10%. 
These are alarming observations and require further 
prospective validation. Van Breemen et al.3, studied the 
use of both valproate as first choice, and in combination 
with newer anti-epileptic levetiracetam. The combination 
of these two medications resulted in 81.5% responders, 
with 55.6% of patients showing a tangible decline in 
seizure frequency. They recommended that the 
combination of an older with newer drug, can be a useful 
therapeutic option in brain tumour patients with resistant 
seizures. 
In another study Novy J et al.4, retrospectively reviewed 
the use of pregabalin (non-enzyme-inducing antiepileptic 
drug) in GBM patients with seizures. All subjects 
experienced at least a 50% seizure reduction. The authors 
recommended pregabalin as an effective anti-epileptic in 
patients with brain tumours and seizures. Its quick 
titration also makes it a good alternative in subjects 
experiencing frequent seizures and the drug can also be 
used in combination with other anti-epileptics like 
levetiracetam, lamotrigine, topiramate, gabapentin and 
valproic acid as a first-line treatment.4 However, so far it is 
not being used as a first line anti-epileptic drug. 
Zonisamide (ZNS), a second-generation anti-epileptic 
drug, has demonstrated efficacy as an add-on in 
refractory epilepsy with simple and complex partial 
seizures, with or without secondary generalization. The 
pharmacokinetics of ZNS include rapid absorption, high 
bioavailability, and a long elimination half-life. The most 
common adverse effects of ZNS (somnolence, weight loss, 
and cognitive impairment) were mild to moderate and 
there were no interactions with concomitant anti-
epileptic drugs.ZNS does not alter patients' perception of 
their quality of life and there also appears to be a 
significant improvement in distress related to cognitive 
disturbances and social functions.5 
In patients with brain tumours, phenytoin used to be the 
drug of choice for prophylactic peri-operative 
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administration, as well as for seizure control. However, it 
was associated with drug interactions due to its induction 
of CYP P450 enzymes. In contrast, levetiracetam is not 
metabolized by the CYP complex in the liver and 
undergoes renal excretion with minimal drug interaction. 
In a phase 2 prospective randomized trial, Iuchi et al.6, 
showed levetiracetamto have a significantly lower 
incidence of perioperative seizures (1.4%) compared to 
phenytoin (15.1%). In addition, levetiracetam appeared a 
a safer drug, and treatment was completed in all patients, 
compared to phenytoin that had to be withdrawn in 6.8% 
of patients. Levetiracetam, in several studies including a 
meta-analysis, has shown efficacy comparable to 
phenytoin, with reduced cost and adverse effects.7 Also, 
due to the advantage of not having to check its serum 
levels, easy titration and minimal drug interactions, 
levetiracetam is fast becoming the first line anti-epileptic 
for brain tumour patients.  
Tumour localization in the frontal lobe and levetiracetam 
treatment have been associated with high risk of neuro-
psychiatric adverse effects in patients with brain tumour 
related epilepsy. This leads to poor compliance and 
higher dropout rates, and therefore, these patients need 
to be closely monitored as outpatients.8 The other 
adverse effect to look for is somnolence, as reported by 
Rosati A et al.9, in a prospective study, where although 73 
of 82 (91%) glioma patients  were seizure free with 
levetiracetam as monotherapy, somnolence was 
occasionally reported in the initial period of therapy. 
Finally, epigenetic modifications may occur in patients 
with GBM, such as changes in gene methylation and 
histone acetylation states. It has been proposed that 
secondary mechanism of action of anti-epileptic drugs, 
that also impact these epigenetic modifications, may play 
a role in effectivity of treatment and survival. Both 
valproate and carbamazepine have HDACi activities, 
while valproate and levetiracetam reduce the activity of 
MGMT, a DNA-repair molecule implicated in resistance to 
alkylating agents used for chemotherapy.10 The use of 
such drugs for purposes other than seizure control has at 
the moment, very little evidence to support its use, but 
does present an interesting area of research.11 
Conclusion 
Seizures in patients with brain tumour can be managed 
effectively by the use of one of many anti-epileptic drugs, 
either as monotherapy, or as combinations. The choice of 
anti-epileptic drugs, depends on several factors and has 
to be individualized according to patients’ response. 
Newer drugs such as levetiracetam, have better tolerance 
and safety profile, and may be employed either as 
monotherapy, or as an add-on with conventional anti-
epileptic drugs. 
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